Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients
- Author
- TANSWELL, Paul1 ; GARIN-CHESA, Pilar2 ; RETTIG, Wolfgang J2 ; WELT, Sydney3 ; DIVGI, Chaitanya R4 ; CASPER, Ephraim S5 ; FINN, Ronald D4 ; LARSON, Steven M4 ; OLD, Lloyd J3 ; SCOTT, Andrew M6
[1] Department of Pharmacokinetics and Drug Metabolism, Bochringer Ingelheim Pharma KG, Biberach, Germany
[2] Department of Oncological Research, Bochringer Ingelheim Pharma KG, Biberach, Germany
[3] Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Centre, New York, NY, United States
[4] Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Centre, New York, NY, United States
[5] Memorial Sloan Kettering Cancer Centre at St. Clare's, Denville, NJ, United States
[6] Ludwig Institute for Cancer Research, Austin & Repatriation Medical Centre, Heidelberg, Victoria, Australia - Source
British journal of clinical pharmacology. 2001, Vol 51, Num 2, pp 177-180 ; ref : 12 ref
- CODEN
- BCPHBM
- ISSN
- 0306-5251
- Scientific domain
- Pharmacology drugs
- Publisher
- Blackwell Science, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Anticorps monoclonal Essai clinique phase I Homme Pharmacocinétique Tumeur maligne Voie intraveineuse Anticorps monoclonal F19 Pharmacocinétique population Protéine activation fibroblaste
- Keyword (en)
- Antineoplastic agent Monoclonal antibody Phase I trial Human Pharmacokinetics Malignant tumor Intravenous administration
- Keyword (es)
- Anticanceroso Anticuerpo monoclonal Ensayo clínico fase I Hombre Farmacocinética Tumor maligno Vía intravenosa
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R01 General aspects
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 902205
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1111/j.1365-2125.2001.01335.x 
https://dx.doi.org/10.1111/j.1365-2125.2001.01335.x
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2125.2001.01335.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients\";s:9:\"\u0000*\u0000jtitle\";s:40:\"British journal of clinical pharmacology\";s:9:\"\u0000*\u0000stitle\";s:22:\"Br. j. clin. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"51\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"177\";s:8:\"\u0000*\u0000epage\";s:3:\"180\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0306-5251\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TANSWELL\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Paul\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:18:\"GARIN-CHESA, Pilar\";i:1;s:18:\"RETTIG, Wolfgang J\";i:2;s:12:\"WELT, Sydney\";i:3;s:18:\"DIVGI, Chaitanya R\";i:4;s:17:\"CASPER, Ephraim S\";i:5;s:14:\"FINN, Ronald D\";i:6;s:16:\"LARSON, Steven M\";i:7;s:12:\"OLD, Lloyd J\";i:8;s:15:\"SCOTT, Andrew M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCPHBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Blackwell Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2125.2001.01335.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients\";s:9:\"\u0000*\u0000jtitle\";s:40:\"British journal of clinical pharmacology\";s:9:\"\u0000*\u0000stitle\";s:22:\"Br. j. clin. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"51\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"177\";s:8:\"\u0000*\u0000epage\";s:3:\"180\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0306-5251\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TANSWELL\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Paul\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:18:\"GARIN-CHESA, Pilar\";i:1;s:18:\"RETTIG, Wolfgang J\";i:2;s:12:\"WELT, Sydney\";i:3;s:18:\"DIVGI, Chaitanya R\";i:4;s:17:\"CASPER, Ephraim S\";i:5;s:14:\"FINN, Ronald D\";i:6;s:16:\"LARSON, Steven M\";i:7;s:12:\"OLD, Lloyd J\";i:8;s:15:\"SCOTT, Andrew M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCPHBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Blackwell Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2125.2001.01335.x\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2125.2001.01335.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients\";s:9:\"\u0000*\u0000jtitle\";s:40:\"British journal of clinical pharmacology\";s:9:\"\u0000*\u0000stitle\";s:22:\"Br. j. clin. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"51\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"177\";s:8:\"\u0000*\u0000epage\";s:3:\"180\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0306-5251\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TANSWELL\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Paul\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:18:\"GARIN-CHESA, Pilar\";i:1;s:18:\"RETTIG, Wolfgang J\";i:2;s:12:\"WELT, Sydney\";i:3;s:18:\"DIVGI, Chaitanya R\";i:4;s:17:\"CASPER, Ephraim S\";i:5;s:14:\"FINN, Ronald D\";i:6;s:16:\"LARSON, Steven M\";i:7;s:12:\"OLD, Lloyd J\";i:8;s:15:\"SCOTT, Andrew M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCPHBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Blackwell Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2125.2001.01335.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients\";s:9:\"\u0000*\u0000jtitle\";s:40:\"British journal of clinical pharmacology\";s:9:\"\u0000*\u0000stitle\";s:22:\"Br. j. clin. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"51\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"177\";s:8:\"\u0000*\u0000epage\";s:3:\"180\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0306-5251\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TANSWELL\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Paul\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:18:\"GARIN-CHESA, Pilar\";i:1;s:18:\"RETTIG, Wolfgang J\";i:2;s:12:\"WELT, Sydney\";i:3;s:18:\"DIVGI, Chaitanya R\";i:4;s:17:\"CASPER, Ephraim S\";i:5;s:14:\"FINN, Ronald D\";i:6;s:16:\"LARSON, Steven M\";i:7;s:12:\"OLD, Lloyd J\";i:8;s:15:\"SCOTT, Andrew M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCPHBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Blackwell Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2125.2001.01335.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients\";s:9:\"\u0000*\u0000jtitle\";s:40:\"British journal of clinical pharmacology\";s:9:\"\u0000*\u0000stitle\";s:22:\"Br. j. clin. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"51\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"177\";s:8:\"\u0000*\u0000epage\";s:3:\"180\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0306-5251\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TANSWELL\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Paul\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:18:\"GARIN-CHESA, Pilar\";i:1;s:18:\"RETTIG, Wolfgang J\";i:2;s:12:\"WELT, Sydney\";i:3;s:18:\"DIVGI, Chaitanya R\";i:4;s:17:\"CASPER, Ephraim S\";i:5;s:14:\"FINN, Ronald D\";i:6;s:16:\"LARSON, Steven M\";i:7;s:12:\"OLD, Lloyd J\";i:8;s:15:\"SCOTT, Andrew M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCPHBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Blackwell Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
